Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4486 to 4500 of 7691 results

  1. Further research should include details of patient selection and report longer term outcomes.

    Recommendation ID IPG777 Question Further research should include details of patient selection and report longer term outcomes. Any

  2. Further research should include details of patient selection, durability and the incidence of complications. Outcomes should be published.

    Recommendation ID IPG642/1 Question Further research should include details of patient selection, durability and the incidence of complications

  3. Further research should report:

    Recommendation ID IPG773 Question Further research should report: Any explanatory notes(if applicable) details of patient

  4. Further research should report details of patient selection, duration of the effect (including whether repeat procedures are needed), and long term outcomes.

    Recommendation ID IPG771 Question Further research should report details of patient selection, duration of the effect (including whether

  5. Further research should report details of patient selection, nodule size and position, and whether the nodule is cystic.

    Recommendation ID IPG643/1 Question Further research should report details of patient selection, nodule size and position, and whether

  6. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    Recommendation ID TA235/1 Question Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical

  7. Further evidence to address the uncertainties in the current clinical evidence,including the impact of gammaCore on all treatments and care as well as itslong-term benefits, would be welcome.

    Recommendation ID MTG46/1 Question Further evidence to address the uncertainties in the current clinical evidence,including the impact

  8. What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum primary care, or for people whose symptoms return after surgery?

    Recommendation ID CG184/4 Question What specialist management is effective for people whose symptoms do not respond to PPIs despite optimum

  9. What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in people with uninvestigated dyspepsia that does not respond to PPIs or H 2   receptor antagonists (H 2 RAs) despite optimum primary care?

    Recommendation ID CG184/5 Question What specialist investigations should be conducted to exclude a diagnosis of functional dyspepsia in

  10. Gathering information in schools or nurseries:- Does routine additional information from educational settings (such as nursery or school) improve accuracy in diagnosing autism among children or young people up to the age of 19 compared with signs and symptoms alone?

    Recommendation ID CG128/2 Question Gathering information in schools or nurseries:- Does routine additional information from educational

  11. Further research is recommended on how using sex-specific 99th percentile thresholds affects treatment decisions and clinical outcomes for men and women.

    Recommendation ID DG40/2 Question Further research is recommended on how using sex-specific 99th percentile thresholds affects treatment

  12. Further research is recommended on patient acceptability of using virtual chromoendoscopy for real-time assessment of diminutive polyps compared with assessment using histopathology

    Recommendation ID DG28/1 Question Further research is recommended on patient acceptability of using virtual chromoendoscopy for real-time

  13. Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal Pathogen Panel, the FilmArray GI Panel and the Faecal Pathogens B assay.

    Recommendation ID DG26/1 Question Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal